A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients
Highlights • This is the first model-based meta-analysis for sofosbuvir-based HCV treatments. • Significant covariates have been identified as virological response predictors. • Modelisation of virological response enables the simulation of clinical trials. • Therapy with sofosbuvir + ledipasvir is...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2016-03, Vol.47 (3), p.184-194 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 194 |
|---|---|
| container_issue | 3 |
| container_start_page | 184 |
| container_title | International journal of antimicrobial agents |
| container_volume | 47 |
| creator | Pérez-Pitarch, Alejandro Guglieri-López, Beatriz Ferriols-Lisart, Rafael Merino-Sanjuán, Matilde |
| description | Highlights • This is the first model-based meta-analysis for sofosbuvir-based HCV treatments. • Significant covariates have been identified as virological response predictors. • Modelisation of virological response enables the simulation of clinical trials. • Therapy with sofosbuvir + ledipasvir is probably the most effective combination. |
| doi_str_mv | 10.1016/j.ijantimicag.2015.12.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1773428398</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857916000030</els_id><sourcerecordid>1773428398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-891f756d58745a9fbfe73c5b6c942ad25cdc4a763c2f22e5f8f51b1aa5b9afeb3</originalsourceid><addsrcrecordid>eNqNkT2P1DAQhi0E4paDv4BCR5PgjziOG6TT6viQTqIAGhpr4ow5L0m82M5J--9xtAtCVLixJT_vjOYZQl4x2jDKujeHxh9gyX72Fr43nDLZMN5Q2j8iO9YrXivNxGOyo5q3dS-VviLPUjrQAopWPiVXvNNMtqrbkW831RxGnOoBEo7VjBlqWGA6JZ-q4KoUXEjD-uDjhcgRIc-45FT5pbL3MSzeVvd4hOxzyeyr7bX9PydPHEwJX1zua_L13e2X_Yf67tP7j_ubu9q2gue618wp2Y2yV60E7QaHSlg5dFa3HEYu7WhbUJ2w3HGO0vVOsoEByEGDw0Fck9fnuscYfq6Yspl9sjhNsGBYk2FKiZb3QvcF1WfUxpBSRGeO0c8QT4ZRs6k1B_OXWrOpNYyborZkX17arMOM45_kb5cF2J8BLMM-eIwm2SLC4ugj2mzG4P-rzdt_qtjJF8Uw_cATpkNYY1lPmcqkEjCftx1vK2YdLUdQ8QsRaqbl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1773428398</pqid></control><display><type>article</type><title>A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Pérez-Pitarch, Alejandro ; Guglieri-López, Beatriz ; Ferriols-Lisart, Rafael ; Merino-Sanjuán, Matilde</creator><creatorcontrib>Pérez-Pitarch, Alejandro ; Guglieri-López, Beatriz ; Ferriols-Lisart, Rafael ; Merino-Sanjuán, Matilde</creatorcontrib><description>Highlights • This is the first model-based meta-analysis for sofosbuvir-based HCV treatments. • Significant covariates have been identified as virological response predictors. • Modelisation of virological response enables the simulation of clinical trials. • Therapy with sofosbuvir + ledipasvir is probably the most effective combination.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2015.12.008</identifier><identifier>PMID: 26915476</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antiviral Agents - therapeutic use ; Benzimidazoles - therapeutic use ; Drug Therapy, Combination ; Female ; Fluorenes - therapeutic use ; Hepacivirus - drug effects ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Humans ; Imidazoles - therapeutic use ; Infectious Disease ; Male ; Meta-analysis ; Modelling ; Models, Theoretical ; Simeprevir - therapeutic use ; Simulation ; Sofosbuvir ; Sofosbuvir - therapeutic use</subject><ispartof>International journal of antimicrobial agents, 2016-03, Vol.47 (3), p.184-194</ispartof><rights>2016 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>Copyright © 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-891f756d58745a9fbfe73c5b6c942ad25cdc4a763c2f22e5f8f51b1aa5b9afeb3</citedby><cites>FETCH-LOGICAL-c432t-891f756d58745a9fbfe73c5b6c942ad25cdc4a763c2f22e5f8f51b1aa5b9afeb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2015.12.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26915476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez-Pitarch, Alejandro</creatorcontrib><creatorcontrib>Guglieri-López, Beatriz</creatorcontrib><creatorcontrib>Ferriols-Lisart, Rafael</creatorcontrib><creatorcontrib>Merino-Sanjuán, Matilde</creatorcontrib><title>A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Highlights • This is the first model-based meta-analysis for sofosbuvir-based HCV treatments. • Significant covariates have been identified as virological response predictors. • Modelisation of virological response enables the simulation of clinical trials. • Therapy with sofosbuvir + ledipasvir is probably the most effective combination.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fluorenes - therapeutic use</subject><subject>Hepacivirus - drug effects</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Imidazoles - therapeutic use</subject><subject>Infectious Disease</subject><subject>Male</subject><subject>Meta-analysis</subject><subject>Modelling</subject><subject>Models, Theoretical</subject><subject>Simeprevir - therapeutic use</subject><subject>Simulation</subject><subject>Sofosbuvir</subject><subject>Sofosbuvir - therapeutic use</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkT2P1DAQhi0E4paDv4BCR5PgjziOG6TT6viQTqIAGhpr4ow5L0m82M5J--9xtAtCVLixJT_vjOYZQl4x2jDKujeHxh9gyX72Fr43nDLZMN5Q2j8iO9YrXivNxGOyo5q3dS-VviLPUjrQAopWPiVXvNNMtqrbkW831RxGnOoBEo7VjBlqWGA6JZ-q4KoUXEjD-uDjhcgRIc-45FT5pbL3MSzeVvd4hOxzyeyr7bX9PydPHEwJX1zua_L13e2X_Yf67tP7j_ubu9q2gue618wp2Y2yV60E7QaHSlg5dFa3HEYu7WhbUJ2w3HGO0vVOsoEByEGDw0Fck9fnuscYfq6Yspl9sjhNsGBYk2FKiZb3QvcF1WfUxpBSRGeO0c8QT4ZRs6k1B_OXWrOpNYyborZkX17arMOM45_kb5cF2J8BLMM-eIwm2SLC4ugj2mzG4P-rzdt_qtjJF8Uw_cATpkNYY1lPmcqkEjCftx1vK2YdLUdQ8QsRaqbl</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Pérez-Pitarch, Alejandro</creator><creator>Guglieri-López, Beatriz</creator><creator>Ferriols-Lisart, Rafael</creator><creator>Merino-Sanjuán, Matilde</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients</title><author>Pérez-Pitarch, Alejandro ; Guglieri-López, Beatriz ; Ferriols-Lisart, Rafael ; Merino-Sanjuán, Matilde</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-891f756d58745a9fbfe73c5b6c942ad25cdc4a763c2f22e5f8f51b1aa5b9afeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fluorenes - therapeutic use</topic><topic>Hepacivirus - drug effects</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Imidazoles - therapeutic use</topic><topic>Infectious Disease</topic><topic>Male</topic><topic>Meta-analysis</topic><topic>Modelling</topic><topic>Models, Theoretical</topic><topic>Simeprevir - therapeutic use</topic><topic>Simulation</topic><topic>Sofosbuvir</topic><topic>Sofosbuvir - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez-Pitarch, Alejandro</creatorcontrib><creatorcontrib>Guglieri-López, Beatriz</creatorcontrib><creatorcontrib>Ferriols-Lisart, Rafael</creatorcontrib><creatorcontrib>Merino-Sanjuán, Matilde</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez-Pitarch, Alejandro</au><au>Guglieri-López, Beatriz</au><au>Ferriols-Lisart, Rafael</au><au>Merino-Sanjuán, Matilde</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>47</volume><issue>3</issue><spage>184</spage><epage>194</epage><pages>184-194</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Highlights • This is the first model-based meta-analysis for sofosbuvir-based HCV treatments. • Significant covariates have been identified as virological response predictors. • Modelisation of virological response enables the simulation of clinical trials. • Therapy with sofosbuvir + ledipasvir is probably the most effective combination.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26915476</pmid><doi>10.1016/j.ijantimicag.2015.12.008</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2016-03, Vol.47 (3), p.184-194 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1773428398 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Antiviral Agents - therapeutic use Benzimidazoles - therapeutic use Drug Therapy, Combination Female Fluorenes - therapeutic use Hepacivirus - drug effects Hepatitis C virus Hepatitis C, Chronic - drug therapy Humans Imidazoles - therapeutic use Infectious Disease Male Meta-analysis Modelling Models, Theoretical Simeprevir - therapeutic use Simulation Sofosbuvir Sofosbuvir - therapeutic use |
| title | A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A07%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20model-based%20meta-analysis%20of%20sofosbuvir-based%20treatments%20in%20chronic%20hepatitis%20C%20patients&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=P%C3%A9rez-Pitarch,%20Alejandro&rft.date=2016-03-01&rft.volume=47&rft.issue=3&rft.spage=184&rft.epage=194&rft.pages=184-194&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2015.12.008&rft_dat=%3Cproquest_cross%3E1773428398%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1773428398&rft_id=info:pmid/26915476&rft_els_id=S0924857916000030&rfr_iscdi=true |